#Surgical Hemostatic Agents Market Growth

[mj2994-me-blog]

Surgical Hemostatic Agents Market Market Insights: Regional Developments, Top Players, and Future Trends 2024-2032

Surgical Hemostatic Agents Market Insights

Reed Intelligence has recently added a new report to its vast depository titled Global Surgical Hemostatic Agents Market. The report studies vital factors about the Global Surgical Hemostatic Agents Market that are essential to be understood by existing as well as new market players. The report highlights the essential elements such as market share, profitability, production, sales, manufacturing, advertising, technological advancements, key market players, regional segmentation, and many more crucial aspects related to the Surgical Hemostatic Agents Market.

Get Free Sample Report PDF @ https://reedintelligence.com/market-analysis/global-surgical-hemostatic-agents-market/request-sample

Surgical Hemostatic Agents Market Share by Key Players

Johnson & Johnson

Takeda (Corza Health)

BD

Baxter

B. Braun

Pfizer

Teleflex

Medtronic

Integra LifeSciences

Ferrosan Medical Devices

GELITA

Advanced Medical Solutions

Medtrade Products

Marine Polymer Technologies

Eurasian AG

Betatech Medical

Equimedical

Important factors like strategic developments, government regulations, market analysis, end users, target audience, distribution network, branding, product portfolio, market share, threats and barriers, growth drivers, latest trends in the industry are also mentioned.

Surgical Hemostatic Agents Market Segmentation

The report on Global Surgical Hemostatic Agents Market provides detailed segmentation by type, applications, and regions. Each segment provides information about the production and manufacturing during the forecast period of 2024-2032. The application segment highlights the applications and operational processes of the industry. Understanding these segments will help identify the importance of the various factors aiding to the market growth.

The report is segmented as follows:

Segmentation By Type

Thrombin Hemostats

Oxidized Regenerated Cellulose Hemostats

Combination Hemostats

Gelatin Hemostat

Collagen Hemostats

Segmentation By Application

Hospitals

Retail

Government/Military

Surgical Hemostatic Agents Market Segmentation by Region

North America

U.S.

Canada

Europe

Germany

UK

France

Asia Pacific

China

India

Japan

Australia

South Korea

Latin America

Brazil

Middle East & Africa

UAE

Kingdom of Saudi Arabia

South Africa

Get Detailed Segmentation @ https://reedintelligence.com/market-analysis/global-surgical-hemostatic-agents-market/segmentation

The market research report on the Global Surgical Hemostatic Agents Market has been carefully curated after studying and observing various factors that determine the growth, such as environmental, economic, social, technological and political status of the regions mentioned. Thorough analysis of the data regarding revenue, production, and manufacturers gives out a clear picture of the global scenario of the Surgical Hemostatic Agents Market. The data will also help key players and new entrants understand the potential of investments in the Global Surgical Hemostatic Agents Market.

Key Highlights

It provides valuable insights into the Global Surgical Hemostatic Agents Market.

Provides information for the years 2024-2032. Important factors related to the market are mentioned.

Technological advancements, government regulations, and recent developments are highlighted.

This report will study advertising and marketing strategies, market trends, and analysis.

Growth analysis and predictions until the year 2032.

Statistical analysis of the key players in the market is highlighted.

Extensively researched market overview.

Buy Surgical Hemostatic Agents Market Research Report @ https://reedintelligence.com/market-analysis/global-surgical-hemostatic-agents-market/buy-now

Contact Us:

Email: sales@reedintelligence.com

[stevenwilliam12]

Hemostasis Market Outlook, Size, and Forecast to 2032: Examining Prevalence of Chronic Diseases and Key Hemostasis Companies

The hemostasis market, essential in trauma and surgical care, plays a critical role in controlling bleeding and facilitating recovery. As surgical procedures advance and the prevalence of chronic diseases rises, the demand for effective hemostasis solutions is increasing. The market includes a diverse range of products like topical hemostats, advanced surgical sealants, and adhesion prevention solutions, all of which are integral to managing blood loss and stabilizing surgical fields, ultimately supporting improved patient outcomes.

Hemostasis Market Outlook and Insights

The hemostasis market outlook is promising, driven by a rise in surgical procedures, increased trauma cases, and an aging global population. Technological advancements have resulted in innovative hemostatic products, such as biologically derived sealants, fibrin-based agents, and advanced collagen-based solutions, which offer faster and more effective action. This growth is further supported by heightened awareness among healthcare providers about the importance of using advanced hemostasis solutions to improve patient outcomes. While North America currently leads in market share due to its robust healthcare infrastructure, the Asia-Pacific region is expected to experience substantial growth, propelled by improved healthcare access and expanding patient populations.

Key Hemostasis Companies in the Market

Leading hemostasis companies such as Abbott Laboratories, Baxter International, Inc., Medtronic plc, CSL Behring LLC, and C. R. Bard, Inc. (BD) play a significant role in shaping the competitive landscape of the hemostasis market. These companies are committed to research and development, driving innovations that enhance the efficacy and biocompatibility of hemostatic agents. Through expanding their portfolios and targeting emerging markets, these companies are strategically positioned to meet the growing demand for hemostasis products globally.

Hemostasis Epidemiology and the Role of Chronic Diseases

The need for hemostasis solutions spans various patient demographics, particularly among those with coagulopathies, trauma-related injuries, and patients undergoing complex surgeries. In developed regions, high rates of trauma cases and elective surgeries, including cardiovascular, orthopedic, and organ transplant procedures, contribute significantly to hemostatic interventions. Additionally, aging populations worldwide, who are more likely to require surgical procedures and are prone to bleeding complications, drive demand for advanced hemostasis solutions. The increasing prevalence of chronic diseases like cancer and cardiovascular disorders also sustains demand, as these patients often require hemostatic support during treatment and recovery.

Hemostasis Market Forecast to 2032

The hemostasis market is projected to experience robust growth through 2032, with a strong CAGR. Key factors influencing this growth include continuous innovation, greater adoption of minimally invasive surgeries, and a heightened focus on blood management during surgical procedures. Hemostasis companies are prioritizing R&D investments to develop highly efficient, biocompatible hemostatic products and are extending their market presence in emerging regions. These efforts are expected to drive the global hemostasis market to new heights, playing a crucial role in advancing patient care and safety worldwide.

Conclusion

In summary, the hemostasis market outlook for 2032 is highly positive, with technological advancements, increased awareness, and a growing patient population spurring demand for reliable blood control solutions. This market will continue to be pivotal in enhancing surgical and trauma care, while the rising prevalence of chronic diseases and the proactive involvement of top hemostasis companies reinforce a bright future for the industry.

Latest Reports

Contraceptive Devices Market | Crohns Disease Cd Market | Cutaneous T-cell Lymphoma Market | Diabetic Neuropathy Market | Ehlers-danlos Syndrome Market | Encephalitis Market | Epidermolysis Bullosa Market | Familial Amyloid Polyneuropathy Market | Healthcare Competitive Benchmarking | Hepatic Encephalopathy Epidemiology Forecast | Hepatitis B Virus Market | Hepatitis D Market | Hereditary Spastic Paraplegias Market | Hpv-induced Cancers Market | Human Papillomavirus Positive Cancer Market | Hyperkalemia Market | Nontuberculous Mycobacteria Infection Market | Post-bariatric Hypoglycemia Market | Postsurgical Pain Market | Primary Progressive Multiple Sclerosis Ppms Market | Surgical Stapling Devices Market | Vascular Access Devices Market | Vascular Dementia Market | Wound Closure Devices Market | Xerostomia Market

[insightfulblogz]

Hemostats Market Growth, Industry Trends, Manufacturers, and Forecast by 2032

Hemostats are indispensable tools in surgical procedures, designed to control bleeding and facilitate clotting to ensure a safer and more efficient surgical environment. They are available in various forms, including mechanical clamps, absorbable sponges, and topical agents that aid in coagulation. Hemostats play a critical role in preventing blood loss during surgery, particularly in complex procedures such as cardiovascular, neurosurgical, and orthopedic surgeries. Their ability to minimize blood loss and reduce the risk of post-operative complications makes them essential for both routine and high-risk surgeries, improving patient outcomes and recovery times.

The Hemostats Market Size was valued at USD 2.8 billion in 2023, and is expected to reach USD 5.06 billion by 2032, and grow at a CAGR of 6.8% over the forecast period 2024-2032.

Future Scope

The future of hemostats lies in the development of advanced materials and bioactive agents that offer faster and more effective clotting capabilities. Research is focusing on creating next-generation hemostats that incorporate biocompatible and biodegradable materials to enhance tissue integration and minimize adverse reactions. Additionally, nanotechnology and bioengineering innovations are expected to produce hemostats that can deliver targeted therapeutic agents to accelerate healing. The integration of smart hemostats, capable of monitoring bleeding in real-time and adjusting their function accordingly, represents a potential game-changer for the industry.

Trends

Several trends are driving innovation in the hemostat market. One of the most notable is the increasing demand for absorbable and biodegradable hemostats that reduce the need for removal after surgery and promote natural healing. Another emerging trend is the use of combination products that integrate hemostatic agents with tissue adhesives or antimicrobial properties to reduce infection risks and improve wound closure. There is also a growing emphasis on developing more effective hemostats for minimally invasive surgeries, which require specialized tools to control bleeding in confined spaces. In addition, technological advancements are enabling the production of faster-acting and more potent hemostats.

Applications

Hemostats are used in a wide range of surgical procedures, from routine operations to complex cardiovascular and neurosurgical interventions. They are critical in trauma surgery, where rapid bleeding control is essential to patient survival. Hemostats are also employed in dental procedures, plastic surgeries, and urological surgeries, where precision in managing blood flow is vital. Beyond the operating room, hemostatic agents are used in emergency medicine to manage traumatic injuries and bleeding disorders.

Get Sample Copy of the Report: https://www.snsinsider.com/sample-request/3086 

Key Points

Hemostats control bleeding and promote clotting during surgical procedures.

Future developments focus on biocompatible, biodegradable, and smart hemostats.

Trends include absorbable hemostats and products with antimicrobial properties.

Hemostats are used in trauma, cardiovascular, neurosurgical, and emergency care.

Advancements in nanotechnology are paving the way for more effective hemostats.

Conclusion

Hemostats are a cornerstone of surgical safety, providing essential bleeding control that improves patient outcomes and enhances the efficiency of surgical procedures. As technological advancements continue to push the boundaries of hemostat development, the future holds great promise for more biocompatible, biodegradable, and intelligent products. These innovations will help reduce surgical risks, promote faster healing, and expand the range of applications for hemostatic solutions, solidifying their place in modern medicine.

[rupalic]

Driving Efficiency with Specialty Enzymes: A Look at Technological Advancements

Specialty enzymes are specific proteins designed to catalyse biochemical reactions for specialized applications in various industries. These enzymes are tailored to meet the unique requirements of different industrial processes, enhancing efficiency, specificity, and performance. The global specialty enzymes market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5%.

Key Applications of Specialty Enzymes:

Food and Beverage Industry:

Baking: Enzymes like amylases and proteases improve dough handling and bread quality.

Dairy: Lactases break down lactose, aiding in the production of lactose-free products.

Brewing: Proteases and beta-glucanases improve filtration and clarity in beer production.

Pharmaceuticals:

Therapeutic Enzymes: Used to treat diseases such as enzyme replacement therapies for lysosomal storage disorders.

Diagnostic Enzymes: Enzymes like glucose oxidase are used in biosensors for blood glucose monitoring.

Biofuels:

Cellulases and Hemicellulases: Break down plant biomass into fermentable sugars for ethanol production.

Lipases: Enhance biodiesel production by breaking down fats and oils.

Textile Industry:

Amylases: Remove starch-based sizing agents from fabrics.

Cellulases: Provide a soft finish to fabrics and improve color brightness.

Agriculture:

Phytases: Improve the bioavailability of phosphorus in animal feed, enhancing nutrition.

Proteases: Enhance the digestibility of feed proteins for better animal growth.

Enzymes sourced from animals hold a significant specialty enzymes market share

Animal-derived enzymes are often preferred for their high specificity and efficiency in catalyzing biochemical reactions, which is essential in various specialized processes. Pancreatic enzymes, such as trypsin and chymotrypsin, are extensively used in drug formulation and the production of biologics. These enzymes facilitate the precise cleavage of peptide bonds, crucial for developing and manufacturing therapeutic proteins and peptides. Their specificity and activity levels make them indispensable in pharmaceutical applications, significantly contributing to their market share.

Moreover, animal-derived enzymes are essential in clinical diagnostics. For example, rennet, obtained from the stomachs of calves, is used in the coagulation process for cheese production, highlighting their importance in the food industry. In clinical settings, enzymes like lactase, derived from animal sources, are used in diagnostic kits to test for lactose intolerance, demonstrating their versatility and utility in both food processing and medical diagnostics.

A notable example of the significance of animal-sourced enzymes is the use of thrombin, derived from bovine sources, in surgical procedures. Thrombin is crucial for promoting blood clotting and is used in topical hemostatic agents to control bleeding during surgeries. The high efficacy and reliability of thrombin in medical applications underscore the importance of animal-derived enzymes in the specialty enzymes market.

Factors Driving the Specialty Enzymes Market Growth

Public funding and incentives for biotechnological research are critical drivers of growth and innovation in the specialty enzymes market. The EU’s Horizon Europe program, with a budget of USD 103.6 billion for 2021-2027, is focused on research and innovation, including biotechnology. This program supports projects aimed at developing advanced biotechnological processes and products. In the United States, the National Institutes of Health (NIH) allocated over USD 42.0 billion for biomedical research in 2022, with part of this funding directed towards biotechnology research, including the development of novel enzymes for medical and industrial applications.

In India, the Biotechnology Industry Research Assistance Council (BIRAC) plays a significant role in fostering innovation and growth within the specialty enzymes market. Established by the Department of Biotechnology (DBT), Government of India, BIRAC actively supports biotech startups and research institutions through various funding schemes. One of the key initiatives is the Biotechnology Ignition Grant (BIG) scheme, which provides early-stage funding to startups and entrepreneurs with innovative ideas in biotechnology. In July 2020, BIRAC allocated Rs. 50 crores (approximately USD 6.7 million) under the BIG scheme to support around 100 startups and entrepreneurs in the biotechnology sector. This funding aims to catalyze innovation, encourage entrepreneurship, and accelerate the development of novel enzyme-based solutions for various applications in biotechnology and pharmaceuticals. By providing financial support and fostering a conducive ecosystem for research and development, initiatives like BIRAC’s BIG scheme contribute significantly to the growth and competitiveness of the enzyme market in India.

Top Specialty Enzymes Companies

BRAIN Biotech AG (Germany)

Novozymes A/S (Denmark)

Codexis, Inc. (US)

Sanofi (France)

Merck KGaA (Germany)

Dyadic International Inc (US)

Advanced Enzyme Technologies (India)

Amano Enzyme Inc (Japan)

F. Hoffmann-La Roche Ltd (Switzerland)

New England Biolabs (US)

BBI Solutions (UK)

North America region to dominate the specialty enzymes industry during the forecast period.

North America holds the highest market share in the specialty enzymes market due to several key factors. The region is home to a robust pharmaceutical and biotechnology industry, characterized by significant investments in research and development. This investment landscape fosters innovation, leading to the development of advanced enzyme-based solutions. For instance, companies like Codexis, Inc. (US), are at the forefront of enzyme engineering, continuously developing new enzymes for pharmaceutical and industrial applications.

Moreover, the presence of well-established healthcare infrastructure and a high demand for diagnostic tools contribute to the market’s growth. Specialty enzymes are crucial in various diagnostic applications, including ELISA (Enzyme-Linked Immunosorbent Assay) tests, which are widely used in medical diagnostics. The increasing prevalence of chronic diseases such as cancer and diabetes in North America drives the demand for these advanced diagnostic tools, further propelling the specialty enzymes industry.

[heathcareforallworld]

Antihemorrhagic Agent Market: Projected Growth and Key Trends Through 2032

The global antihemorrhagic agent market is gaining substantial traction due to the growing prevalence of bleeding disorders and the rising number of surgeries. Antihemorrhagic agents, also known as hemostatic agents, play a crucial role in controlling excessive bleeding, making them an essential component in surgeries, trauma care, and treating coagulation disorders. This article provides an in-depth analysis of the antihemorrhagic agent market, projecting its trends, drivers, challenges, and forecasts until 2032.

Market Overview

Antihemorrhagic agents are employed to promote blood clotting and reduce blood loss in cases of severe bleeding. These agents can be categorized into two types: systemic agents and local hemostatic agents. Systemic agents such as desmopressin, tranexamic acid, and aminocaproic acid work by affecting the blood's ability to clot. Local hemostatic agents, such as fibrin sealants and gelatin sponges, are applied directly to the bleeding site to halt blood flow.

Antihemorrhagic Agent Market Size was estimated at 3.22 (USD Billion) in 2023. The Antihemorrhagic Agent Market Industry is expected to grow from 3.39(USD Billion) in 2024 to 5.2 (USD Billion) by 2032. The Antihemorrhagic Agent Market CAGR (growth rate) is expected to be around 5.48% during the forecast period (2025 - 2032).The rising demand for efficient bleeding control solutions in both surgical and emergency settings is fueling market growth.

Key Market Drivers

Increasing Surgical Procedures: With an increase in surgical interventions, especially in cardiovascular and orthopedic surgeries, the demand for antihemorrhagic agents has surged. These agents are vital in minimizing intraoperative and postoperative bleeding, reducing recovery time, and improving patient outcomes.

Growing Trauma Cases: The rise in road accidents and trauma cases is another key factor driving the market. Emergency treatments for traumatic injuries often require immediate bleeding control, making antihemorrhagic agents indispensable.

Prevalence of Hemophilia and Other Coagulation Disorders: The increasing number of individuals diagnosed with bleeding disorders like hemophilia has driven the demand for effective antihemorrhagic therapies. Patients with these conditions require frequent treatments to manage spontaneous bleeding episodes.

Technological Advancements: The development of advanced hemostatic agents, including novel fibrin sealants and faster-acting clotting factors, is enhancing the effectiveness of these products. Innovations in bioengineered hemostats are expected to further propel market growth.

Challenges Facing the Market

Despite its growth prospects, the antihemorrhagic agent market faces several challenges that could potentially hinder its expansion.

High Cost of Treatment: Many advanced antihemorrhagic agents, particularly biologically derived products, can be expensive, limiting their accessibility in low- and middle-income countries. Additionally, the cost of repeated treatments for chronic bleeding disorders can place a financial burden on patients and healthcare systems.

Side Effects and Risks: Some antihemorrhagic agents may cause adverse reactions such as blood clot formation in unintended areas, leading to serious complications like stroke or deep vein thrombosis. This risk is particularly high in systemic agents.

Regulatory Hurdles: Strict regulatory frameworks and the lengthy approval processes for new antihemorrhagic products can delay their market entry. Furthermore, rigorous clinical trials are required to demonstrate the efficacy and safety of these agents, which can be time-consuming and costly.

Regional Insights

North America currently dominates the global antihemorrhagic agent market, accounting for over 40% of the market share in 2023. The high number of surgeries, widespread adoption of advanced medical technologies, and well-established healthcare infrastructure in the region are key contributors to this dominance. The United States is a major market due to the rising number of trauma cases and increasing awareness of bleeding disorders.

Europe holds the second-largest market share, with countries such as Germany, France, and the United Kingdom leading the region's market growth. The presence of leading pharmaceutical companies and a growing number of patients requiring surgical interventions drive demand in this region.

The Asia-Pacific region is expected to witness the highest growth rate over the forecast period. Rapidly improving healthcare facilities, rising healthcare expenditure, and a growing geriatric population are key factors contributing to this growth. Countries like China, India, and Japan are anticipated to lead the market expansion in this region.

Future Market Outlook

The antihemorrhagic agent market is set to witness significant growth over the next decade, driven by advancements in medical technology and increasing demand for efficient bleeding control solutions. The development of next-generation hemostatic agents with faster action and reduced side effects will likely accelerate market growth. Additionally, the growing awareness of bleeding disorders and the need for emergency trauma care will further fuel demand for these agents globally.

Conclusion

The global antihemorrhagic agent market is on a strong growth trajectory, supported by the increasing number of surgical procedures, the prevalence of bleeding disorders, and advancements in hemostatic technology. While challenges such as high treatment costs and regulatory hurdles persist, innovations in the sector are expected to open new avenues for market expansion through 2032.

Other reports:

 Aortic Anastomosis Clamps market

 Apheresis Station market

 Arginine Hydrochloride Injection market

 Arm Ergometer market

 Arthritis And Joint Pain Management Solution market

[globalinsightsservices]

The Hemostats Market is a critical player in the evolution of surgical procedures, offering life-saving solutions that control bleeding during operations. As minimally invasive surgeries gain traction, the demand for effective and reliable hemostatic agents is on the rise. From traditional mechanical hemostats to advanced topical agents, the market is expanding with innovations that enhance surgical outcomes and patient safety. With continuous advancements and the rising number of surgical procedures worldwide, the Hemostats Market is poised for significant growth, playing an indispensable role in modern healthcare.

[healthcarehubhh]

Bone Glue Market will grow at highest pace owing to increasing demand in orthopedic surgeries.

Bone glue is a type of sealing and hemostatic agent that helps join together pieces of bones fractured due to accidents or undergoes orthopedic surgeries and procedures like spinal fusion. It forms a strong bond between bones like glue and consolidates the bone fragments in their original position to trigger natural bone healing. Bone glue is easy to use, less invasive and provides immediate fixation of bone fragments compared to metal plates or screws used traditionally in orthopedic surgeries. The use of bone glue helps save surgery time, decreases post-surgical pain, and does not require any implant removal surgery. Growing sports injuries, road accidents and increasing aging population suffering from osteoporosis and orthopedic conditions are fueling demand for bone glue globally. The Global Bone Glue Market is estimated to be valued at US$ 2,332.0 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the Bone Glue are Cryolife, Luna Innovations Incorporated., St. Jude Medical, Inc. (Abbott Laboratories), Johnson and Johnson, Cohera Medical Inc, Tissuemed Ltd., Integra Lifesciences Corporation, Baxter International Inc., B.Braun Melsungen AG, DENTSPLY SIRONA Inc., Chemence Medical Inc., LaunchPad Medical, and C.R. Bard Inc. The key players are engaged in new product launches and strategic collaborations to strengthen their market position. The bone glue market is anticipated to witness high growth owing to increasing geriatric population, rising sports, and road injuries. According to the United Nations, between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%. Moreover, as per the Centre of Disease Prevention and Control report 2020, around 3.4 million road traffic accidents occur in India annually with over 1,50,000 road deaths reported in the country. Growing technological advancements to develop innovative biomaterials for bone glues such as genetically engineered adhesives, growth factor incorporated bone glues, and 3D printed implantable bone glues are expected to revolutionize orthopedic treatment procedures over the forecast period. This will further propel the demand for bone glue in orthopedic surgeries globally. Market Trends Growing use of 3D printed bone glues - Researchers are developing advanced 3D printing technologies to fabricate patient-specific bone implants using various biomaterials like synthetic polymers or calcium phosphates that can act as bone glues and hard tissues replacement. 3D printed implants with bone glues are expected to facilitate complex surgeries and accelerate bone healing. Rising popularity of genetically engineered bone glues - Scientists are engineering biological adhesives using advanced gene sequencing and modification techniques. These genetically engineered bone glues are formulated using natural proteins and possess adhesive properties comparable to natural bone structures providing stronger fixation. Market Opportunities - Untapped emerging markets -Majority of bone glue sales currently occur in developed regions of North America and Europe. Emerging nations of Asia Pacific and Latin America offer huge untapped market opportunities with growing healthcare Infrastructure and increasing organizes sports. - Adoption in trauma and accident care hospitals - Though widely adopted in elective orthopedic procedures, increasing promotion and educationactivities can help utilize bone gluing in trauma surgeries too for quick fixation of open fractures in emerging markets.

[pranalipawarshinde]

Hemostats Market overview by recent opportunities, growth size, regional analysis and forecast 2024-2033

“Global Insight Services company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

The Hemostats Market size was USD 3.7 Billion in 2023 and is anticipated to reach USD 6.1 Billion in 2033, growing at a rate of 4.8% from 2024 to 2033.

Hemostat is referred to as a surgical agent that regulates and controls the bleeding process during surgical procedures. Hemostats help to shorten surgery time and reduce the need for blood transfusions. Hemostatic agents are essential in establishing hemostasis in pre-hospital conditions and preventing death associated with hemorrhage. Hemostats are used to compress blood vessels and prevent the flow of blood or other fluids. They are generally used as an adjunct to surgical procedures to manage bleeding. Hemostatic agents offer different benefits, which include decreased wound healing & operative time, better management of anti-coagulated patients, and a reduction in the patient recovery period.

View The Full Report Here –https://www.globalinsightservices.com/reports/hemostats-market

[omkarpatel]

Hemostatic Spray is Estimated to Witness High Growth Owing to Increasing Incidences of Surgeries

Hemostatic sprays are advanced hemostatic agents that provide rapid and effective hemostasis for surgical bleeding. These sprays are composed of modified polysaccharides and thrombin, which promote clotting at bleeding sites. They help surgeons in achieving intraoperative hemostasis and reduce operative blood loss. Hemostatic sprays allow for targeted application of hemostatic agents minimally invasively with precision. The growing number of surgical procedures owing to rising cases of cardiovascular diseases, cancer, accidents and sports injuries has increased demand for hemostatic agents that can effectively manage blood loss during surgeries. The global Hemostatic Spray Market is estimated to be valued at US$ 2.51 Bn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity The increasing number of surgical procedures is one of the major factors fueling growth of the hemostatic spray market. As per the data by the American Cancer Society, over 1.8 million new cancer cases are diagnosed in the US each year. Cancer patients often need to undergo multiple invasive surgeries for tumor removal and tissue resection which leaves them at high risk of excessive blood loss. Hemostatic sprays are effective in controlling bleeding during such complex surgeries. Their wide availability in the market and ability to cover larger treatment areas is expected to drive their adoption among medical professionals in cancer and other multi-organ surgeries. This increasing demand from surgery centers will present lucrative growth opportunities for players in the hemostatic spray market during the forecast period. Porter's Analysis Threat of new entrants: The threat of new entrants is moderate in the hemostatic spray market due to high R&D costs and testing involved to gain regulatory approvals. However, growing number of mid-sized companies is expected to gradually erode barriers to entry. Bargaining power of suppliers: The bargaining power of suppliers is moderate due to availability of alternative suppliers of raw materials. However, stringent regulations ensure quality which provides some bargaining power to suppliers. Competitive rivalry: The competitive rivalry is high due to presence of large number of players offering differentiated products. Players focus on new product launches, geographical expansion and mergers & acquisitions for competitive advantage. SWOT Analysis Strengths: Growing application in trauma cases and surgeries is a key market driver. Advanced products with efficacy, ease of use and quick hemostasis provide competitive edge. Weaknesses: High costs of advanced products limit adoption in price sensitive markets. Side effects associated with few ingredients also act as a restraint. Opportunities: Untapped potential in emerging economies with large surgical volumes and trauma cases present growth opportunities. Growing healthcare spending is likely to aid market growth. Key Takeaways The global hemostatic spray market is expected to witness high growth over the forecast period driven by expanding applications in trauma and surgery coupled with product innovations. The global Hemostatic Spray Market is estimated to be valued at US$ 2.51 Bn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030. North America currently dominates due to robust healthcare infrastructure and higher procedural volumes for trauma and surgeries in the region. Asia Pacific region comprises large population, improving access to healthcare and growing medical tourism offering opportunities for market players. The region is expected to grow at a high rate during the forecast period. Key players operating in the hemostatic spray market are Olympus Corporation, Medtronic plc., Shilpa Medicare Limited, Baxter, BC3 Technologies, Ethicon, Pfizer Inc., HemCon Medical Technologies, Z-Medica, Teleflex Incorporated, Tricol Biomedical, Arch Therapeutics, and Cook.

[marketsizereports]

An Overview of the North America Topical Absorbable Hemostat Procedures Market: Trends and Insights

The North America topical absorbable hemostat procedures market is a critical segment of the healthcare industry, providing vital solutions to control bleeding during surgical and medical procedures. This overview offers insights into the current trends and key dynamics shaping the market in North America.

For more insights on the North America Topical Absorbable Hemostat Procedures market forecasts, download a free sample report

Market Overview:

The North America topical absorbable hemostat procedures market encompasses the United States and Canada, serving a wide range of medical applications, including cardiovascular surgery, general surgery, orthopedics, and more. Topical absorbable hemostats are indispensable in these procedures to enhance patient safety, reduce complications, and optimize surgical outcomes.

Key Market Trends and Insights:

Technological Advancements: The market is witnessing continuous advancements in the technology behind topical absorbable hemostats. These innovations aim to improve their effectiveness, ease of use, and speed of achieving hemostasis.

Growth in Minimally Invasive Surgery: The increasing adoption of minimally invasive surgical techniques is driving the demand for topical absorbable hemostats, which are crucial for controlling bleeding through smaller incisions. Their effectiveness in these procedures contributes to better patient recovery.

Expanded Use in Cardiovascular Surgery: Cardiovascular procedures, including heart surgeries, have seen an expanded use of absorbable hemostats. These products play a pivotal role in managing bleeding in delicate cardiac surgeries, reducing the risk of complications.

Wider Adoption in Orthopedics: The orthopedic field is increasingly recognizing the value of topical absorbable hemostats, especially in joint replacement and trauma surgeries. These agents effectively minimize blood loss, leading to improved patient outcomes.

Focus on Healthcare Cost Efficiency: Healthcare providers are seeking cost-effective solutions, and topical absorbable hemostats align with this objective. By reducing the risk of complications and shortening hospital stays, they contribute to healthcare cost-efficiency.

Regulatory Scrutiny: Regulatory bodies are paying closer attention to hemostatic agents, which may lead to evolving regulations and safety standards for these products. Compliance with these regulations will be essential for manufacturers and healthcare institutions.

Patient Safety: Patient safety remains a top priority in healthcare. The use of absorbable hemostats is an essential component of minimizing the risks associated with bleeding complications during surgical procedures.

Supply Chain Challenges Amid COVID-19: The COVID-19 pandemic has had mixed effects on the market. While the increased demand for medical procedures and surgeries has driven the need for hemostatic agents, disruptions in the supply chain have presented challenges. Ensuring a stable supply of these critical products remains a priority.

In conclusion, the North America topical absorbable hemostat procedures market is marked by technological innovation and a growing emphasis on patient safety and healthcare cost-efficiency. The continued expansion of their use across various surgical specialties underscores the essential role of these products in modern healthcare. Manufacturers, healthcare institutions, and regulatory bodies must collaborate to ensure the safety and efficacy of these critical medical solutions. As the healthcare landscape evolves, the market for topical absorbable hemostats is expected to continue adapting to meet changing needs and standards.

[pranay-234]

Thrombin Market Dynamics and Growth Prospects till 2032

In the intricate world of healthcare, it's the smallest components that often make the biggest differences. Thrombin, an enzyme that plays a pivotal role in blood coagulation, is one such element that can't be overlooked. This article delves into the Thrombin Market, analyzing its size, share, and the trends that are shaping its future.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐎𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 : https://www.alliedmarketresearch.com/request-toc-and-sample/8761

COVID-19 Scenario analysis

The COVID-19 pandemic has been a global health crisis of unprecedented proportions, reshaping industries and creating new challenges for healthcare and pharmaceutical sectors. In this context, let's explore how the Thrombin Market, a critical component in healthcare, has been influenced by the pandemic.

Pharmaceutical and Biotech Response

Pharmaceutical and biotech companies, in collaboration with governments globally, have been at the forefront of addressing the COVID-19 outbreak. Their focus ranged from developing vaccines to ensuring the supply chain of essential medicines remained unbroken.

Vaccine Development: A monumental effort was dedicated to vaccine development, with approximately 115 vaccine candidates in the research and development pipeline. This extensive initiative aimed to curb the spread of COVID-19.

Rising Demand for Drugs: Certain drugs, including Hydroxychloroquine, experienced a surge in demand as they were initially explored for COVID-19 management. This increased demand presented both challenges and opportunities for drug manufacturers.

Impact on the Thrombin Market

The high demand for COVID-19 management drugs, including Thrombin, brought about notable shifts and challenges:

Production Challenges: With the pharmaceutical industry's diversion towards COVID-19 management, the production of critical drugs like Thrombin faced challenges due to shifting priorities.

Supply Chain Disruptions: The pandemic disrupted global supply chains, affecting the availability and distribution of medical supplies, potentially impacting the availability of Thrombin.

𝐏𝐫𝐞-𝐛𝐨𝐨𝐤 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐨𝐰 : https://www.alliedmarketresearch.com/thrombin-market/purchase-options

Understanding Thrombin's Crucial Role

Thrombin is a key player in the body's ability to stop bleeding. It converts soluble fibrinogen into insoluble strands of fibrin, creating a blood clot. Without it, even minor injuries could lead to excessive bleeding.

Market Size and Share Analysis

The Thrombin Market encompasses various applications, including surgical procedures, wound care, and diagnostics. Here's a snapshot of its size and share:

Surgical Procedures: Thrombin is indispensable in surgical settings, where it's used to control bleeding during operations. This segment holds a significant share in the market.

Wound Care: Thrombin-based products are vital in wound care, facilitating quicker and more efficient healing. The wound care segment is witnessing steady growth.

Diagnostics: In diagnostics, Thrombin plays a role in tests related to coagulation disorders. This segment is relatively smaller but continues to evolve.

Industry Trends Shaping the Market

Rise in Surgical Procedures: The increasing number of surgical procedures, driven by factors such as an aging population and advances in medical technology, is boosting the demand for Thrombin in the surgical segment.

Wound Care Advancements: Innovations in wound care, such as the development of Thrombin-based hemostatic agents, are contributing to the growth of this segment.

Regulatory and Quality Standards: Stricter regulatory and quality standards are shaping the industry, ensuring the safety and efficacy of Thrombin-based products.

Focus on Research and Development: Ongoing research into Thrombin's applications and the development of novel formulations is expanding the market's horizons.

𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐭𝐨 𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐭𝐡𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 : https://www.alliedmarketresearch.com/purchase-enquiry/8761

Future Outlook

The future of the Thrombin Market appears promising. As the healthcare landscape evolves and the need for effective hemostatic agents persists, Thrombin is poised to play an increasingly vital role. With advancements in surgery, wound care, and diagnostics, this humble enzyme continues to be a game-changer in healthcare.

In conclusion, the Thrombin Market's size, share, and trends underline its significance in the medical world. As it evolves, the market's growth prospects appear robust, promising innovative solutions for critical healthcare needs. Thrombin, an unassuming yet essential component of healthcare, is here to stay and make a substantial impact on patient care and medical advancements.

 About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

[sanemyamen]

Thrombin Market to Witness Excellent Revenue Growth Owing to Rapid Increase in Demand

Latest business intelligence report released on Global Thrombin Market, covers different industry elements and growth inclinations that helps in predicting market forecast. The report allows complete assessment of current and future scenario scaling top to bottom investigation about the market size, % share of key and emerging segment, major development, and technological advancements. Also, the statistical survey elaborates detailed commentary on changing market dynamics that includes market growth drivers, roadblocks and challenges, future opportunities, and influencing trends to better understand Thrombin market outlook. List of Key Players Profiled in the study includes market overview, business strategies, financials, Development activities, Market Share and SWOT analysis are Pfizer (United States),Johnson & Johnson Servicess, Inc. (United States),Octapharma AG (Switzerland),Baxter International Inc. (United States),Bayer AG (Germany),CSL Limited (Australia),Grifols, S.A. (Spain),GE Healthcare (United States),Hualan Biological (China) Thrombin is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Thrombin is available in many forms as a hemostatic agent and has been purified from numerous sources and classified according to the plasma used to create it. Thrombin has high growth prospects owing to the rising prevalence of blood clotting disorders and increasing surgical activities. Key Market Trends: Rising Adoption of Smoking increasing the Prevalence of Thrombosis

Opportunities: Increasing Surgical Procedure due to Increasing Number of Diseases Worldwide

Growth and Advancement in Technology in the Healthcare Industry in Developing Countries

Market Growth Drivers: Growing Prevalence of Blood Clotting Disorders

Growth in the Use of Thrombin due to Adoption of Hemostats in Excessive Bleeding during Surgical Procedure Challenges: Ineffective in Patients who Suffer from Afibrinogenemia

The Global Thrombin Market segments and Market Data Break Down by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory Surgical Centers, Academics & Research Institutes)

Presented By

AMA Research & Media LLP

[meditech-insights]

Hemostats Market Key Facts and Insights on Future Scenario To 2026

Hemostasis is the body’s natural response to an injury that stops bleeding and repairs the damage. The ability helps in conserving blood and prevents infection. Hemostats are surgical instruments used in surgical procedures to control bleeding.

The Global Hemostats Market was valued at US$ 2.7 billion in 2021 and is set to witness a healthy growth rate of 6% in the next 5 years. Increase in surgical procedures (related to cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, dentistry, obstetrics, and gynecology), rising cases of trauma, technological advancements in hemostats, shrinking blood supply/donor pool in several countries, and advance opportunities in emerging markets are some of the main factors driving the global hemostats market.

Technological Advancements Drive the Global Hemostats Market

Uncontrollable bleeding poses significant fatality risks and costs in the battlefield, emergency, and hospital settings. Therefore, players operating in the market are focusing on developing hemostatic agents that can rapidly control bleeding, possess antibacterial properties, can be used as adjuncts to control bleeding during surgical procedures, and control residual problematic bleeding if conventional methods fail.

In Feb 2022, Futura Surgicare Pvt Ltd.’s new vertical Dolphin Hemostats launched hemostatic products under the brand Hemostax (Oxidised Regenerated Cellulose). Hemostax Standard is an absorbable hemostat that is designed to help surgeons control bleeding more efficiently

In July, 2021, Medcura, Inc. launched a new class of high-performance, antibacterial hemostatic gel, Rapid-Seal®. It provides rapid bleeding management and antibacterial capabilities to improve wound treatment, help fight infections of the wound and create an environment for safe healing

Plastic Surgery - An Untapped Market

Plastic surgery signifies a commercially lucrative opportunity for the hemostats market. Like most surgical procedures, plastic surgery procedures are also not without associated complications. Seromas and hematomas are comparatively common complications associated with plastic surgery procedures. These complications adversely impact wound healing and result in significant morbidity in patients. The use of hemostatic agents can significantly reduce these complications, achieve immediate hemostasis for the local bleeding site, allow earlier drain removal, and possibly avoid the usage of drains altogether.

“Technologically innovative products are likely to be successful in the market. In my opinion, there is only one product in the market that has complementary features of advanced bleeding control and antimicrobial activity.”- Director, Leading Hemostat Manufacturer, United States

Explore Premium Report on Hemostats Market @ https://meditechinsights.com/hemostats-market/

Evolving Markets Set to Drive the Hemostatic Agents Market

Emerging markets such as China, India, and South Korea are expected to witness double-digit growth in the coming years. Growth in emerging markets is likely to be driven by lower-cost hemostatic products that are largely commoditized. The massive volume of surgical procedures, increasing cases of trauma injuries, growing cases of organ transplantation (legal & illegal), foray of local players, and increasing capabilities of surgeons to perform more complex and technically- demanding procedures that require efficacious, fast-acting hemostats to control bleeding are some of the key factors that are expected to drive the demand of hemostatic agents in emerging markets.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in Hemostats Market

The hemostats market is characterized by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as new product launches, and acquisitions to garner market share.

For instance,

In July 2021, Baxter acquired PerClot Polysaccharide Hemostatic System from CryoLife. The acquisition marks Baxter’s entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive hemostatic solutions

In December 2020, Teleflex completed the acquisition of Z-Medica, LLC, an industry-leading manufacturer of hemostatic products.

The global hemostats market is set to continue its growth due to the rise in surgical procedure volumes, technological advancements in hemostats, increasing usage of hemostats in the military, emergency medical services (EMS) & hospitals, and commercial opportunities in minimally invasive surgery (MIS), plastic surgery, and knee replacement surgery.

Competitive Landscape Analysis of Hemostats Market

The global hemostats market is marked by the presence of players such as Baxter, Ethicon, B. Braun, Becton Dickinson, Pfizer, CryoLife, Teleflex (Z-Medica), Integra LifeSciences, Biomup, Medtronic, among others.

For More Comprehensive Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

[rupalic]

Specialty Enzymes Industry Future Outlook, Global Trends, Industry Share And Top Key Players

The specialty enzymes market is poised for growth, driven by technological advancements, expanding applications, and rising health consciousness. However, companies need to navigate regulatory challenges and production costs to capitalize on the market opportunities effectively.

Specialty Enzymes Market Size and Growth

Current Market Size: The specialty enzymes market has been experiencing steady growth, driven by increasing demand across various industries such as pharmaceuticals, biotechnology, food and beverages, and diagnostics.

Projected Growth: According to MarketsandMarkets, the global specialty enzymes market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5%.

Genetic Engineering and Sustainability: Enzymes Leading the Way

Advancements in enzyme engineering have enabled the discovery of new enzymes from natural sources, ensuring their safety and efficacy in various applications. This includes their use in producing specialty pharmaceuticals and in biocatalytic processes. A recent study by the University of Notre Dame researchers in January 2022 emphasized biocatalytic depolymerization as an efficient and sustainable method for plastic treatment, addressing environmental concerns and enhancing recycling efforts. Additionally, the Manchester Institute of Biotechnology (MIB) has developed an enzyme engineering platform to improve plastic degradation using directed evolution techniques. These advancements in genetic engineering and enzymes engineering for sustainable practices highlight the specialty enzymes market’s growth potential, especially in addressing environmental issues and promoting eco-friendly solutions.

Why Are Animal-Sourced Enzymes Gaining Popularity in the Specialty Enzymes Industry?

Animal-derived enzymes are often favored for their high specificity and efficiency in catalyzing biochemical reactions, which are crucial for various specialized processes. Pancreatic enzymes like trypsin and chymotrypsin are widely used in drug formulation and the production of biologics. These enzymes facilitate the precise cleavage of peptide bonds, which is vital for the development and manufacturing of therapeutic proteins and peptides. Their specificity and activity levels make them indispensable in pharmaceutical applications, significantly contributing to their market share.

Request Custom Data to Address your Specific Business Needs

In addition, animal-derived enzymes are essential in clinical diagnostics and the food industry. For example, rennet, obtained from calves’ stomachs, is used in the coagulation process of cheese production. In clinical settings, enzymes like lactase, sourced from animals, are used in diagnostic kits to test for lactose intolerance, demonstrating their versatility in both food processing and medical diagnostics. Moreover, thrombin, derived from bovine sources, plays a crucial role in surgical procedures by promoting blood clotting and is used in topical hemostatic agents to control bleeding during surgeries. The high efficacy and reliability of thrombin in medical applications underscore the importance of animal-derived enzymes in the specialty enzymes industry.

Specialty Enzymes Market Growth Drivers

Pharmaceutical Industry Demand: Specialty enzymes are extensively used in pharmaceutical applications for drug formulation and biocatalysis, boosting market demand.

Advancements in Biotechnology: Innovations in enzyme engineering and biotechnology are enhancing enzyme efficiency and expanding their application range.

Food and Beverage Industry: Enzymes play a crucial role in improving food quality, processing, and shelf life, increasing their demand in this sector.

Rising Health Awareness: Growing consumer preference for natural and organic products is driving the demand for enzymes in nutraceuticals and dietary supplements.

North America Specialty Enzymes Set to Lead the Market

North America holds the largest specialty enzymes market share in the specialty enzymes sector, driven by several key factors. The region boasts a strong pharmaceutical and biotechnology industry, supported by substantial investments in research and development. This investment climate encourages innovation, resulting in the creation of advanced enzyme-based solutions. Companies like Codexis, Inc. (US) lead the way in enzyme engineering, consistently developing new enzymes for pharmaceutical and industrial uses.

Additionally, North America’s well-established healthcare infrastructure and high demand for diagnostic tools contribute to market growth. Specialty enzymes play a vital role in various diagnostic applications, such as ELISA (Enzyme-Linked Immunosorbent Assay) tests, which are extensively used in medical diagnostics. The rising prevalence of chronic diseases, including cancer and diabetes, in North America further fuels the demand for these advanced diagnostic tools, boosting the specialty enzymes market.

2024's Game-Changing Innovations in Specialty Enzymes: Recent Advances

In March 2024, Biocatalysts, part of the BRAIN Biotech Group, enhanced its production capacity by adding a large-scale freeze-drying facility at its Cardiff site. This new facility would support the customization and precise formulation of enzymes for the food, beverage, and life sciences industries. By complying with kosher, halal, ISO9001:2015, and FSSC22000 standards, the facility ensured high-quality and flexible enzyme production.

In March 2024, Merck invested over USD 324.68 million in a new bioprocessing production center in Daejeon, South Korea, marking its largest life science investment in the Asia Pacific. This expansion, expected to create around 300 jobs by 2028, underscores Merck’s commitment to enhancing its capacity in this rapidly growing region.

In March 2024, Sanofi India Limited (SIL) approved an agreement with Emcure Pharmaceuticals to exclusively distribute and promote SIL’s Cardiovascular products in India. While SIL retains ownership, import, and manufacturing, Emcure would enhance engagement with healthcare professionals and broaden the reach, benefiting patients nationwide and strengthening Sanofi’s market presence.

Top Specialty Enzymes Companies

BRAIN Biotech AG (Germany)

Novozymes A/S (Denmark)

Codexis, Inc. (US)

Sanofi (France)

Merck KGaA (Germany)

Dyadic International Inc (US)

Advanced Enzyme Technologies (India)

Amano Enzyme Inc (Japan)

F. Hoffmann-La Roche Ltd (Switzerland)

New England Biolabs (US)

BBI Solutions (UK)

Make an Inquiry to Address your Specific Business Needs

[healthcare-domain]

The Future of Endoluminal Suturing Devices Market

The global endoluminal suturing devices market is projected to reach USD 139 million by 2027 from USD 78 million in 2022, at a CAGR of 12.0%. Growth in this market is majorly driven by the rising prevalence of gastrointestinal cancers, inflammatory bowel disease, and other digestive diseases and the increasing number of surgical procedures worldwide.

Endoluminal Suturing Devices Market DynamicsDriver: Increasing number of surgical procedures worldwide

Endoluminal suturing devices are widely used in open surgeries, abdominal surgeries, endoscopy, and other gastrointestinal surgeries. Over the years, the affordability and accessibility to surgical care have increased, leading to a significant rise in the number of surgical procedures performed utilizing suturing devices. The increasing prevalence of lifestyle diseases and the subsequent rise in surgical procedures have further increased the demand for advanced surgical equipment, including suturing devices.

Restraint: Presence of alternative wound care management products

Wound closure devices such as staplers, ligating clips, and wound closure strips and sealing agents, skin adhesives, and hemostats are prominent alternatives associated with certain advantages to surgical sutures.  

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=250924884

For instance, stapling is quicker than suturing. Due to their efficiency and benefits over surgical sutures, the availability of alternatives is a key restraint for the endoluminal suturing devices market.

Opportunity: High growth opportunities in emerging markets

Emerging countries (such as China, Brazil, Mexico, and India) present significant growth opportunities for players in the endoluminal suturing devices market. The demand for endoluminal suturing devices in these countries is increasing owing to the rapid growth in the healthcare infrastructure, increasing public and private healthcare expenditure, and growth in medical tourism.

Currently, the lack of skilled surgeons in developed and developing economies is one of the major factors limiting the adoption of endoluminal suturing devices. While the demand for surgeons is steadily increasing, the supply of future surgeons is not rising at the same rate. Therefore, this shortage will likely reduce the number of surgeries performed annually, negatively impacting the adoption of endoluminal suturing devices.

Key Market Players

Major players in the endoluminal suturing devices market are Apollo Endosurgery, Inc. (US), Johnson & Johnson (US), Medtronic Plc (Ireland), Cook Group Incorporated (US), USGI Medical (US), Ovesco Endoscopy AG (Germany), Endo Tools Therapeutics S.A. (Belgium), ErgoSuture (US), and Sutrue Ltd. (UK).

[medi-techinsights]

Global Hemostats Market valued at $2.7 billion in 2021, is set to witness a healthy growth rate of 6% by 2026

Hemostasis is the body’s natural reaction to an injury that stops bleeding and repairs the damage. The capability helps in conserving blood and prevents infection. Hemostats are surgical tools that are used in surgical procedures to control bleeding.

Technological Advancements are driving the Hemostats Market

Uncontrollable bleeding poses substantial fatality risks and costs in the battlefield, emergency, and hospital settings. To address these concerns, players operating in the market are focusing on developing hemostatic agents that can rapidly control bleeding, possess antibacterial properties, can be used as adjuncts to control bleeding during surgical procedures, and control residual problematic bleeding if conventional methods fail.

In Feb 2022, Futura Surgicare Pvt Ltd.’s new vertical Dolphin Hemostats launched hemostatic products under the brand Hemostax (Oxidised Regenerated Cellulose). Hemostax Standard is an absorbable hemostat that is designed to help surgeons control bleeding more efficiently

In July, 2021, Medcura, Inc. launched a new class of high-performance, antibacterial hemostatic gel, Rapid-Seal®. It provides rapid bleeding management and antibacterial capabilities to improve wound treatment, help fight infections of the wound and promote an environment for safe healing

Plastic Surgery - An Untapped and Growing Market

Plastic surgery represents a commercially lucrative opportunity for the hemostats market. Similar to most surgical procedures, plastic surgery procedures are also not without associated complications. Seromas and hematomas are relatively common complications associated with plastic surgery procedures. These complications adversely impact wound healing and result in substantial morbidity in patients. The use of hemostatic agents can significantly reduce these complications, achieve immediate hemostasis for the local bleeding site, allow earlier drain removal, and potentially avoid the use of drains altogether.

“Technologically advanced products are likely to be successful in the market. I think, there is only one product in the market that has complementary characteristics of advanced bleeding control and antimicrobial activity.” - Director, Leading Hemostat Manufacturer, United States

Emerging Markets Set to Drive the Hemostatic Agents Market

Emerging markets such as China, India, and South Korea are expected to witness double-digit growth in the coming years. The growth in the emerging markets is likely to be driven by lower-priced hemostatic products that are largely commoditized. The huge volume of surgical procedures, rising cases of trauma injuries, increasing cases of organ transplantation (legal & illegal), foray of local players, and growing capabilities of surgeons to undertake more complex and technically-challenging procedures that require efficacious, fast-acting hemostats to control bleeding are some of the key factors that are expected to fuel the demand of hemostatic agents in emerging markets.

Growth Strategies Adopted by Leading Market Players

The global hemostats market is marked by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as new product launches, and acquisitions to garner market share. For instance,

In July 2021, Baxter acquired PerClot Polysaccharide Hemostatic System from CryoLife. The acquisition marks Baxter’s entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive hemostatic solutions

In December 2020, Teleflex completed the acquisition of Z-Medica, LLC, an industry-leading manufacturer of hemostatic products.

The global hemostats market is set to continue its growth due to the rise in surgical procedure volumes, technological advancements in hemostats, growing usage of hemostats in the military, emergency medical services (EMS) & hospitals, and commercial opportunities in minimally invasive surgery (MIS), plastic surgery, and knee replacement surgery.

Competitive Landscape Analysis: Global Hemostats Market

The global hemostats market is marked by the presence of key players such as Baxter, Ethicon, B. Braun, Becton Dickinson, Pfizer, CryoLife, Teleflex (Z-Medica), Integra LifeSciences, Biomup, Medtronic, etc.

Browse Detailed Market Research Insights on Hemostats Market @ https://meditechinsights.com/hemostats-market/